August J. Troendle, President and CEO of Medpace Holdings, Inc. (NASDAQ:MEDP), filed a Form 4 on August 27, 2026, disclosing the sale of 4,673 shares of common stock across two transactions on August 25 and August 26, 2026.

Key Highlights

  • August 25 sale: Troendle sold 673 shares of common stock at a weighted average price of $620.38, in multiple transactions ranging from $620.00 to $621.89.
  • August 26 sale: Troendle sold 4,000 shares at a weighted average price of $620.03, in multiple transactions ranging from $620.00 to $620.54.
  • Direct ownership following transactions: Troendle directly holds 540,544 shares of common stock after both sales.
  • Indirect ownership: Troendle indirectly holds 4,733,019 shares through Medpace Investors, LLC, of which he is the sole manager and controlling unit holder.
  • Transaction basis: Both sales were effected pursuant to a limit order placed during an open window period, according to the filing.

Troendle's Share Sales and Beneficial Ownership at Medpace Holdings

According to the Form 4 filed with the SEC, Troendle, who serves as President, CEO, and Director of Medpace Holdings, Inc., disposed of a combined 4,673 shares of common stock over two consecutive trading days. The August 25, 2026, transaction involved 673 shares sold at a weighted average price of $620.38, with individual trades ranging from $620.00 to $621.89. The following day, 4,000 shares were sold at a weighted average price of $620.03, with individual trades ranging from $620.00 to $620.54. The filing notes that both transactions were conducted via a limit order placed during an open window period.

Following these disposals, the filing reports Troendle's direct beneficial ownership at 540,544 shares. In addition, the filing discloses that Troendle indirectly beneficially owns 4,733,019 shares through Medpace Investors, LLC. According to the filing, Troendle "is the sole manager and controlling unit holder of Medpace Investors, LLC" and "has sole voting and investment control with respect to the securities held by MPI." The filing further states that Troendle "disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."

The filing was signed by Stephen P. Ewald as Attorney-in-Fact for August J. Troendle and dated August 27, 2026. The reporting person has undertaken to provide full pricing details on both transactions to the issuer, any security holder, or SEC staff upon request.

What Was Disclosed

Medpace Holdings President and CEO August J. Troendle reported the sale of 4,673 shares of common stock on August 25 and 26, 2026, executed via limit orders during an open window period, with direct holdings of 540,544 shares remaining afterward.